DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

HIV Infections Clinical Trial

— D3 (Penta21)  

Official title:

A Randomised Non-inferiority Trial With Nested PK to Assess DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04337450
• Other study ID #: D3 (Penta21)
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: April 22, 2022
• Est. completion date: July 31, 2025

Study information

• Verified date: September 2023
• Source: PENTA Foundation
• Contact: Anna Turkova, MSc
• Phone: +4402076704658
• Email: a.turkova[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to find out whether treating children and young people living with HIV with two anti HIV medicines, dolutegravir and lamivudine, is safe and as effective as the three-medicine anti-HIV treatments currently used in routine practice.

Description:

This study will include 370 children and young people aged 2 to less than 15 years old who are living with HIV and are being treated with anti-HIV medicines for the first time. Participants will be split into two groups, by chance, by a process called "randomisation". One group will continue to receive the anti-HIV medicines already taken according to country-specific routine practice. The second group will change to the new combination of medicine, dolutegravir and lamivudine (with the combination written usually as "DTG/3TC"). Depending on the weight, participants in the second group will be able take the new medicine either as one tablet a day or as a small number of dispersible tablets that are also taken once a day. All children and young people in the study will have regular clinic assessments that are at a similar frequency to the clinic visits that participants would have outside of the study. Blood tests will be performed to check that the medicine is safe and, at some visits, participants and their carers will also be asked to answer some questions on how they feel about taking their medicine. All children and young people will be followed until the last participant who joins the study has been in the study for 96 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 370
• Est. completion date: July 31, 2025
• Est. primary completion date: September 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 15 Years

Eligibility

Inclusion Criteria:

1. HIV-1 infected children who are virologically suppressed for at least the last 6 months prior to enrolment

2. Aged 2 to <15 years old

3. Weight 6 kg or higher

4. Children on the same triple-drug PI/r, NNRTI or INSTI containing ART regimen for at least 3 months

5. Girls who have reached menarche must have a negative pregnancy test at screening and randomisation

6. Girls who are sexually active must be willing to adhere to highly effective methods of contraception

7. A parent or legal guardian is willing and able to give informed consent on behalf of the child as per national legislation and willing to adhere to the protocol

8. Participant is willing to give informed assent if the trial site clinician deems them old enough and able to understand the age-appropriate information about participation in the study

Exclusion Criteria:

1. Any previous switch in ART regimen for virological, immunological or clinical treatment failure

2. Any changes in ART in the last 6 months for reasons other than due to child's growth, drug stock-outs, changes in country guidelines and treatment simplification

3. Evidence of previous resistance to 3TC or INSTI

4. Any prior use of regimens consisting of single or dual NRTIs with the exception of a course of zidovudine for PMTCT

5. Known allergy or contraindications to dolutegravir or lamivudine

6. Diagnosis of tuberculosis and on anti-tuberculosis treatment; children can be enrolled after successful tuberculosis treatment

7. Treatment of co-morbidities with drugs which have significant interactions with antiretroviral treatment, requiring dose adjustment of the study drugs (children can be enrolled after the illness resolves)

8. Randomisation visit more than 12 weeks after the most recent screening visit

9. Evidence of hepatitis B infection with no protective immunity against hepatitis B:

participants positive for HBsAg or HBcAb and negative for HBsAb

10. Anticipated need for hepatitis C virus therapy with interferon-based regimen prior to the primary endpoint.

11. Screening ALT equal to 3 or more times the upper limit of normal AND bilirubin equal to 2 or more times the upper limit of normal (ALT =3xULN AND bilirubin =2xULN)

12. Screening ALT equal to 5 or more times the upper limit of normal ALT (=5xULN)

13. Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

14. Screening creatinine clearance <50 mL/min/1.73m2

15. Patients aged =6 years at moderate or high risk of suicide as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)

16. Girls who are pregnant or breastfeeding

17. Children who are in the legal custody of the State and do not have a parent or guardian able to provide informed consent on their behalf.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Communicable Diseases
• HIV Infections
• Infections

Intervention

Drug:
• Dolutegravir (DTG) and lamivudine (3TC)
Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
• SOC
2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)

Locations

Country	Name	City	State
South Africa	King Edward VIII Hospital	Durban
South Africa	PHRU Klerksdorp	Klerksdorp
South Africa	PHRU	Soweto
Spain	Hospital Universitario 12 de Octubre	Madrid
Thailand	Prapokklao Hospital	Chanthaburi
Thailand	Nakornping Hospital	Chiang Mai
Thailand	Chiangrai Prachanukroh Hospital	Chiang Rai
Thailand	Khon Kaen Hospital	Khon Kaen
Uganda	Baylor	Kampala
Uganda	Joint Clinical Research Centre	Kampala
Uganda	MUJHU	Kampala
United Kingdom	Birmingham Heartlands Hospital	Birmingham
United Kingdom	Great Ormand Street Hospital	London
United Kingdom	St. Mary's Hospital	London

Sponsors (22)

Lead Sponsor

Collaborator

PENTA Foundation

Advanced Pathogens Diagnostics Unit, University College London Hospitals, AMS-CMU/IRD (PHPT), Baylor College of Medicine, Centre for Health Economics, University of York, Chiang Mai University, Chiangrai Prachanukroh Hospital, Chris Hani Baragwanath Academic Hospital, Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands., Department of Molecular and Clinical Pharmacology, University of Liverpool, Durban International Clinical Research Site, Great Ormond Street Hospital for Children NHS Foundation Trust, Hospital Universitario 12 de Octubre, Imperial College Healthcare Trust, St Mary's Hospital, Joint Clinical Research Center, Kalasin Hospital, Kalasin, Khon Kaen Hospital, MRC CTU at UCL, MU-JHU CARE, Nakornping Hospital, Prapokklao Hospital, Chantaburi, University Hospital Birmingham NHS Foundation Trust

Countries where clinical trial is conducted

South Africa,  Spain,  Thailand,  Uganda,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of children with confirmed viral rebound (defined as the first of two consecutive HIV-1 RNA =50c/mL) by week 96		by Week 96
Secondary	Proportion of children with confirmed viral rebound (defined as the first of two consecutive HIV-1 RNA =50c/mL) by week 48		by Week 48
Secondary	Proportion of children with confirmed HIV-1 RNA =50c/mL at weeks 48 and 96 (modified FDA snapshot)		at Week 48 and 96
Secondary	Proportion of children with HIV-1 RNA =50c/mL at weeks 24, 48 and 96 (including blips and confirmed measures =50c/mL)		at Week 24, 48 and 96
Secondary	New resistance-associated mutations in those with confirmed HIV-1 RNA =50c/mL		by Week 96
Secondary	Time to any new or recurrent WHO 3 or WHO 4 event or death		through study completion, up to 5 years
Secondary	Change in CD4 (absolute and percentage) from baseline to weeks 24, 48 and 96		Week 24, 48 and 96
Secondary	Incidence of serious adverse events, grade 3 and 4 clinical and laboratory adverse events		through study completion, up to 5 years
Secondary	Incidence of adverse events leading to discontinuation or modification of the treatment regimen		through study completion, up to 5 years
Secondary	Proportion of children with a change in ART for toxicity or switch to second-line		through study completion, up to 5 years
Secondary	Change in blood lipids from baseline to weeks 48 and 96		Week 48 and 96
Secondary	Change in creatinine clearance estimated using bedside-Schwartz to weeks 48 and 96		Week 48 and 96

External Links

•   Related Info
•   Related Info